Evidence map›Paper›PMID 35737926›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al.

Eva Versteijne, Jacob L van Dam, Marc G Besselink, Bas Groot Koerkamp, Marjolein Y V Homs, Johanna W Wilmink, Casper H van Eijck, Geertjan van Tienhoven

Abstract readComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Eva VersteijneEva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.ORCID 0000-0003-3861-5310
Jacob L van DamEva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.ORCID 0000-0002-6947-9035
Marc G BesselinkEva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.ORCID 0000-0003-2650-9350
Bas Groot KoerkampEva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.ORCID 0000-0003-1917-6973
Marjolein Y V HomsEva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
Johanna W WilminkEva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
Casper H van EijckEva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
Geertjan van TienhovenEva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35737926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.